Cellectis acquired the Vectocell® intracellular delivery technology from Diatos to optimize the efficacy of its drug candidates. This platform reportedly improves the performance of a therapeutic compound by enabling specific entry into the target cell compartment or organ in animals and humans.


It is based on the fusion between the therapeutic protein and an antibody-derived peptide that facilitates passive entry into the cell. Experimental data shows that this targeting technique provokes minimal immunogenicity and thus reportedly offers excellent safety.








This site uses Akismet to reduce spam. Learn how your comment data is processed.